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SO M O
Medicines for the European market are increasingly 
being tested on clinical trial participants in low- and 
middle-income countries (LMICs), where most participants 
are poor and have limited access to health care. Against 
this backdrop, the entitlement to Post-Trial Access to 
Treatment (PTA) after the trial has ended becomes increas-
ingly important to avoid the exploitation of vulnerable 
participants. The problem is that patients are being 
enrolled onto clinical trials in the full knowledge of 
the trial sponsors that they will not have access to the 
continuing treatment they may need once the trial 
has finished. This practice is unethical.
“Because I will get into this trial, I get better, and 
then afterwards I am going to die. You have promised 
me life and then you take it back; that’s not fair.”  
HIV/AIDS Clinical Trial Participant, Kenya 2006
The Good Clinical Practice Guidelines of the International 
Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use (ICH),1 
which have been integrated into European legislation,2 
comprehensively describe the responsibilities and expecta­
tions of those involved in the conduct of clinical trials. 
However, these guidelines do not describe any responsi­
bilities for continuing treatment after the trial. Leading 
international ethical guidelines such as the Declaration 
of Helsinki and the Council for International Organizations 
of Medical Sciences (CIOMS) guidelines include the right 
to PTA, but they use different wording and still raise many 
questions. This lack of firm guidance is fuelling a heated 
academic debate about fundamental ethical questions 
regarding the treatment of patients after clinical trials. 
“In advance of a clinical trial, sponsors, researchers 
and host country governments should make provisions 
for post-trial access for all participants who still need 
an intervention identified as beneficial in the trial. 
This information must also be disclosed to participants 
during the informed consent process.”  
(Article 34, Declaration of Helsinki 2013)
In the midst of this ethical and theoretical debate, what 
happens in practice? How do pharmaceutical companies 
deal with this complex issue with little practical guidance 
and without binding regulations? There is a big gap in 
our knowledge about how the pharmaceutical industry 
currently deals with PTA in practice. The objective of this 
research is to address this gap by offering a collection 
of PTA practices in low­ and middle­income countries, 
as provided by the pharmaceutical industry. q
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The Centre for Research on Multinational Corporations 
(SOMO) approached a number of the biggest pharmaceutical 
companies asking for a good example of a real situation 
in which they arranged and financed the continuation 
of treatment after the completion of a trial in a low­ or 
middle­income country – in other words, we were looking 
for examples of best practice.
Therefore, this paper does not aim to expose individual 
unethical company practices. Instead, it offers an insight 
into current corporate policies and practices relating to 
PTA based on company sources. 
The aim of this paper is to identify elements of corporate 
best practice in relation to PTA. The underlying assumption 
is that this will help to put a realistic standard in place that 
may lead to minimum regulatory rules in the longer term.
Expert: “There is no consensus on what a PTA best 
practice should look like. My personal opinion is that 
if you don’t have an alternative treatment, then you 
should continue with the experimental drug. But if 
there is an available treatment, then you should go 
back to that drug until the regulatory authority 
approves the drug. So there is not one recipe.”
Problem description
While all the phases of a clinical trial are highly regulated, 
including the stage prior to the actual beginning of the trial 
(informed consent process), what happens right after the 
trial is not regulated.
In theory, pharmaceutical companies accept a certain 
degree of responsibility regarding the provision of PTA. 
However, in practice PTA appears to be rarely provided in 
LMICs, where the need for PTA is the greatest. National 
health­care systems in LMICs are often not able to provide 
the follow­up treatment that is needed after the trial. 
This can lead to a situation where patients who have 
received treatment and care through their participation 
in a trial fall back on the insufficient local standard of care 
once the trial is completed (if they have access to treatment 
at all). This can result in the unwanted situation of the 
cessation of a beneficial treatment. 
Methodology
This research focuses on nine of the 20 pharmaceutical 
companies that ranked highest by revenue in 2013. 
The sample of the companies analysed in this paper has 
been influenced by the degree of difficulty in identifying 
and gaining access to relevant people within the companies. 
The selection is therefore linked to the degree of accessi­
bility and responsiveness of the companies on the subject 
of PTA. The findings are not representative for the whole 
sector. However, since we want to highlight the most 
advanced company policies on PTA, our assumption is that 
they are likely to be obtained from the most responsive 
companies on the subject.
Company: “I supervise the department that manages 
clinical trials, so I don’t know anything about the post- 
trial phase. For this point you need to contact our 
global headquarters.”
Nine companies provided answers about their PTA policies 
and practices by email, and five of them agreed to a 
phone interview. SOMO asked for examples of PTA solely 
sponsored by the company provided after a clinical trial 
in an LMIC.3 The requested examples were supposed to 
represent a good example of what the company considers 
to be in line with the international ethical guidelines they 
endorse. Not all the companies were willing or able to 
share examples of PTA matching SOMO’s request, due 
to the fact that they do not keep records on PTA, or the 
information is not for public consumption, or simply 
because PTA is not provided by the company in an LMIC 
as far as the contact person was aware. All companies are 
given the opportunity to review their quotes and the 
presentation of their PTA examples.
Alongside the search for corporate best practice, SOMO 
analysed the company policies on PTA, the strong and 
weak points of international guidelines, and reviewed part 
of the academic debate, without the goal of contributing 
to this debate. 
Reading guidance to the briefing paper
Although the literature on the subject of PTA is quite 
extensive, practical examples are poorly documented, 
both in the literature and on the internet. As previously 
mentioned, this research aims to fill that gap. Starting from 
a review of the current international guidelines and of the 
main streams of academic output on the topic, it will then 
offer a reflection on the most advanced company policies 
on PTA. Examples of what companies indicated as their 
best PTA practice will follow. On the basis of these reviews 
and practices, this paper will then draw some conclusions 
and suggest elements for corporate best practice on PTA. 
Finally, some recommendations for implementation of 
such standards will also be provided.
 3Pharmaceutical sector SOMO Paper
PTA in the international ethical guidelines
We have indicated that it is a problem that international 
ethical guidelines are not aligned. However, existing guide ­ 
lines do contain strong elements that, together, offer enough 
grounds for a strong PTA policy. The review on the next 
page highlights the strongest characteristics of each set 
of guidelines in order to identify what can be considered 
essential for PTA best practice.
PTA in legislation 
Brazil and Argentina6 are currently the only countries where 
there are binding regulations to provide PTA (see Box 1). 
In a few LMICS, such as Uganda, India, South and Africa7 
non­binding national guidelines support the provision of 
PTA. However, these are not mandatory. 
Although the wording in the Argentina law is somewhat 
vague, it is one of the two examples of PTA obligations 
incorporated in national laws.8
PTA in the European Medicines Agency 
reflection paper
The guidance of the European regulatory authority 
(the European Medicines Agency – EMA) on how to deal 
with PTA in LMICs can be found in their reflection paper 
on ethical and good clinical practice aspects of clinical 
trials conducted outside Europe. PTA transparency is of 
paramount importance for the EMA, which requires 
clinical trial sponsors to describe the situation of trial 
participants with regard to PTA and medical care with 
respect to the local situation where the trial is conducted. 
They must describe what provisions were made for PTA 
and medical care and what information was given to the 
patients prior to their consent.9
PTA in the academic debate
Issues around PTA range from medical science, bioethics, 
human rights, law and politics to economics and marketing. 
As a result of this complexity, a vast array of academic 
resources is available to deal with the medical needs and 
ethical, moral, political, legal and practical dilemmas.
For this paper, two main streams of debate are particularly 
relevant. The first stream of academic literature deals with 
the fundamental question about the general desirability 
of PTA; arguments in favour and against PTA are widely 
discussed. In the second stream of debate, academics 
discuss the ethical implications of what appears to be the 
most pragmatic way to provide PTA with an unlicensed 
drug: Open Label Extension Studies.10
A fundamental question: is PTA always 
desirable?
The principle of non­malfeasance (do no harm) is undisputed 
in medicine, and most arguments in favour of PTA refer 
to it. A drug that has proven to be beneficial to someone 
cannot be withdrawn. Moreover, when it comes to LMICs, 
the principles of justice and global ethical standards are 
evoked and contribute to an increasing consensus on 
the desirability of PTA. 
Rank 
(by revenue 2013)
Companies participating 
in the research 
Interview Answers 
by email
Provided examples 
of good PTA practice 
in LMIC
1. Novartis No Yes 1
2. Pfizer No Yes
3. Roche No Yes
4. Sanofi Yes Yes 6
6. GlaxoSmithKline (GSK) Yes Yes 1
8. AstraZeneca Yes Yes 1
9. Eli Lilly Yes Yes
13. Bayer No Yes
18. Gilead Yes Yes 14 
Source: IMS Health, based on revenue 2013.5
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2013 Declaration of Helsinki,11 article 22: 
“In clinical trials, the protocol must also describe 
appropriate arrangements for post­trial provisions.”
2013 Declaration of Helsinki, article 34:12 
“In advance of a clinical trial, sponsors, researchers 
and host country governments should make provisions 
for post­trial access for all participants who still need 
an intervention identified as beneficial in the trial. 
This information must also be disclosed to participants 
during the informed consent process.” 
CIOMS/WHO Guidelines, guideline 5:13 
“Before requesting an individual’s consent to 
participate in research, the investigator must provide 
(the research subjects) the following information (…) 
whether, when and how any products or interven­
tions proven by the research to be safe and effective 
will≈be made available to subjects after they have 
completed their participation in the research, and 
whether they will be expected to pay for them.” 
CIOMS/WHO Guidelines, guideline 10:14 
“Before undertaking research in a population or 
community with limited resources, the sponsor and 
the investigator must make every effort to ensure 
that: (…) any intervention or product developed, 
orknowledge generated, will be made reasonably 
available for the benefit of that population  
or community.”
CIOMS/WHO Guidelines, commentary to 
guideline 10:15 “If an investigational drug has been 
shown to be beneficial, the sponsor should continue 
to provide it to the subjects after the conclusion 
of the study, and pending its approval by a drug 
regulatory authority.”
Nuffield Council on Bioethics:16 “We therefore 
endorse the NBAC recommendation that researchers 
should endeavour before the initiation of a trial to 
secure post­trial access for effective interventions 
for participants in the trial and that the lack of such 
arrangements should have to be justified to a 
research ethics committee.”
 Importance of advanced planning of any 
 provisions of PTA (Declaration of Helsinki – DoH, 
Nuffield Council, CIOMS/World Health 
Organization – WHO). 
 PTA provisions should be described in advance 
both in the clinical trial protocol (DoH) as well 
as in the informed consent forms (DoH, CIOMS/
WHO). 
 Allocation of specific responsibilities to actors 
involved in the trial and post­trial phase should 
be clear prior to the trial (DoH, Nuffield, CIOMS/
WHO). Financial responsibilities in particular 
need to be clearly specified (CIOMS). 
 PTA should be ensured for all participants in the 
trials (Nuffield, CIOMS/WHO), and undoubtedly 
for those who still need an intervention identified 
as beneficial (DoH). 
 The intervention or product developed, or 
 generated knowledge, should be made (reason­
ably) available, not only for trial participants, 
but also for the benefit of that population or 
community (CIOMS/WHO) 
 Effective interventions: These may include but 
should not be limited to the investigational drug 
(Nuffield). It is important to recall here that, 
although no longer en force, the 2008 version17 
of the DoH mentioned that PTA was not limited 
to access to interventions identified as beneficial 
in the study, but it was extended to “other 
appropriate care or benefits”. 
 Lack of PTA arrangements should be justified 
to research ethics.  
International ethical guidelines – strong elements Recap of the strong elements in the guidelines 
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“if need be”. He says that, “Implementation of mandatory 
post­trial provision usually encounters many difficulties, but 
they may be tackled by careful advanced planning”.24 
Along with this larger stream of debate,25 26 Usharani and 
Naqvi identify a number of potential points to ponder 
before considering the provision of PTA: one of them is that 
giving the drug to trial participants while the rest of the 
population does not have access to it can create disparity, 
especially in low­resource settings. Another point is the 
duration of PTA: the feasibility (or otherwise) for the 
sponsor to provide PTA for an unlimited period, especially 
for chronic diseases. Moreover, PTA with an investigational 
drug should be reconsidered when evidence is preliminary 
and exposure to that drug may still be hazardous. Usharani 
and Naqvi highlight the importance of addressing all these 
issues in the clinical trial protocol before regulatory and 
institutional approval. They argue that “providing alternative 
benefits is more feasible for sponsors and can be applied 
uniformly to all subjects rather than agreeing to post­trial 
access” (to the investigational drug).27
Alternative benefits may range from strategies to make 
medical drugs more affordable in developing countries28 
to benefits tailored to specific contexts and negotiated 
with communities when there is no opportunity of direct 
benefit from a specific intervention.29
However, academic experts argue that PTA may not always 
be desirable. During a meeting on PTA organised by SOMO 
and Wemos in June 2012,18 experts voiced some of the 
common objections against the provision of PTA:
	 PTA may cause undue inducement, since the expectation 
of follow­up care or any other benefit, especially in 
LMICs, may persuade people to participate in clinical 
research.19 20
	 PTA may delay trials because of procedures and 
agreements to be made with governments, sponsors, 
researchers and others involved.
	 PTA may prevent trials from happening, since the 
financial burden of PTA provision may become a 
disincentive for sponsors to conduct clinical research, 
especially in LMICs.21 
	 PTA may be misused as a marketing tool, as in the case 
of Long Term Extension studies.22
In their 2011 article, Dainesi and Goldbaum stress that 
decision­making processes about PTA should take into 
account that PTA may not always be appropriate: 
“The decision must be submitted to at least two assessments: 
efficacy and safety of the new experimental drug”.23 
In his 2008 article, on the other hand, Zong highlights 
how much PTA is influenced by contextual circumstances. 
He claims that provision of PTA should be established  
Box 1: National regulations on PTA – the unique case of Brazil 
 
In her interview with SOMO, Dr. Sonia Dainesi, a Brazilian 
leading expert in the field and author of studies on the 
topic of PTA, explained why Brazil is an exception in the 
area of PTA: “The national system is very good, because 
you have to provide PTA by law and you have to include 
the PTA provisions before the trial starts, except if the 
patients don’t benefit of the drug or if the doctor thinks 
it’s not necessary to continue with this drug”.30
The first regulation that addressed access to unregistered 
drugs under expanded access programmes was the RDC 
26/1999.31 Recently, Brazil’s Health Surveillance Agency 
issued a new regulation, RDC 38/2013,32 which further 
expands the access to investigational drugs.
However, Dr. Dainesi explained the shortcomings: 
“Who is responsible for providing the drug is the problem. 
The legislation says that the sponsor is responsible for 
the provision of PTA, which is usually the industry, but not 
always. Sometimes it’s the institutions, or the government, 
or the academia that conduct the studies.”33 However, 
the latter often do not have sufficient funds to grant the 
provision of PTA. The result is that the ethical duty of 
providing PTA and the legally enforceable right of receiving 
it are constantly regulated in courts: “Patients who 
 participate in clinical trials can sue, with a high probability 
of success, either the pharmaceutical company or the 
State to force them to keep providing the experimental 
drug. This has triggered, in turn, further lawsuits in which 
either the state or the pharmaceutical company, when 
sued by the patient, sue each other trying to transfer the 
responsibility to provide the experimental treatment”.34 
The current legal conditions described here contribute 
to making Brazil a very unique case as far as the provision 
of PTA is concerned. Participants have the right to PTA 
as part of their right to health care, but the duty of 
providing it is often decided through litigation.
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In reference to the concept of ‘benefits’, some scholars 
critique the formulation of paragraph 34 in the new version 
of the Declaration of Helsinki. The recent exchange 
of opinions between Del Re and collaborators35 and 
Mastroleo36 demonstrate how definitions of ‘benefits’ 
or ‘other appropriate care’, which were lost in the 2013 
version of the Declaration of Helsinki, are still being 
discussed. The matter is not semantic but rather substantive, 
as it relates to a fair distribution of the benefits of 
clinical research.
The debate on pragmatic choices
Whilst the primary goal of clinical research is to contribute 
to scientific knowledge, the provision of health care is 
based on the ethical principles of treating patients and 
possibly saving their lives. The common practice of ‘Open 
Label Extension Studies’ as a pragmatic way to provide 
PTA with unlicensed drugs results in blurring the lines 
between research and health­care provisions, which are 
fundamentally and practically regulated by different ethical 
principles. This has prompted a stream of debate among 
scholars.37 38 39 40 The issue is concisely expressed by the title 
Cho has given to her paper: “Open­Label Extension Studies: 
are they really research?”41 Authors discussing this topic 
point to the ethical dilemma of using clinical research to 
provide health care. While research has the ultimate objective 
of generating scientific knowledge, the goal of health care 
is to provide health to individuals. This may not coincide 
with the balance of risks/benefits for a clinical trial where in 
principle individuals volunteer to serve research purposes.
As well as highlighting the ambiguity between care and 
research, Open Label Extension (OLE) studies also blur the 
lines between PTA and marketing. Taylor and Wainwright 
published an article that also summarises the ethical dilemma 
in its title: “Open Label Extension studies: research or 
marketing? Who is benefiting the most out of it: the patients 
or the companies?”42 PTA within the context of an OLE 
raises the question whether the company is doing this out 
of compassion or just because it still needs data on the 
long­term safety and tolerability of the investigational 
drug for the marketing applications.
PTA in the companies’ policies and 
practices 
Since many aspects of PTA are still being debated and 
international ethical standards provide little guidance 
regarding what responsibilities a commercial sponsor must 
take and how, pharmaceutical companies are adopting a 
pragmatic approach towards the problem of conducting 
trials among vulnerable or underprivileged populations. 
Some common practices emerge from the analysis of the 
policies published by the companies that collaborated 
with this research and the statements given by the 
companies’ representatives in their interviews with SOMO.
Commitments to PTA
There is a definite lack of clear company commitments in 
reference to the right to PTA. There was one clear statement 
on Novo Nordisk’s website: “Clinical trial participants 
should have access to best proven and available treatment 
after a trial has stopped”.43 Although not comprehensive, 
PTA is mentioned in various company policy documents. 
All nine companies analysed for this research have included 
the Declaration of Helsinki (DoH) in policy documents on 
their websites. Either as a reference instrument for human 
rights (Sanofi44) or as an international ethical guideline 
the company “follows” (GSK45) or “adheres to” (Gilead,46 
Eli Lilly,47 Novartis48) or “complies with” (AstraZeneca,49 
Pfizer50), or operates “in accordance with” (Bayer51), 
or “in full conformance” (Roche52). Including the DoH 
 unreservedly can be seen as a commitment by companies 
to acknowledge the entitlement to PTA.
Disclosure of PTA provisions
The addition to article 34 in the 2013 version of the DoH 
says that PTA provisions must be disclosed to the participants 
during the informed consent process. This is actually 
already part of some company policies: 
Roche: “Before commencing a Roche Sponsored 
Clinical Trial in a low or middle income developing 
country, Roche will ensure that a description of post-
trial drug supply is written and incorporated into the 
protocol and patient informed consent forms.”53
Sanofi: “The issue of PTA is always addressed in the 
study protocol and in the patient information documents 
which are used for soliciting informed consent.”54 
For Sanofi, addressing PTA also means that if it is clear that 
no post­trial treatment will be provided, patients will be 
informed beforehand, and the protocol will indicate the 
rationale for this.55
The practice of these policy statements cannot be verified 
by SOMO because original clinical trial protocols and 
informed consent forms are not made public. Protocol 
summaries in clinical trial registries such as ClinicalTrials.gov56 
do not include a field for the PTA provisions. Also the 
‘WHO Data Set’, which defines the minimum amount of 
trial information that must appear in a register in order for 
a given trial to be considered as fully registered, does not 
include the requirement to give information about 
PTA provisions.57 
SOMO has been informed by Bayer that the company 
keeps a database of Managed Access Programs (MAP) 
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(this definition is used as equivalent to PTA programmes 
by Bayer).58 Bayer is the only company in this research that 
mentioned collecting this kind of information centrally in 
a database, but this is not made publicly available.59
In the absence of a standard definition 
of PTA, is there a standard practice?
Only in exceptional circumstances
Most of the companies included in this research are very 
clear that PTA will only be provided in very specific and 
exceptional circumstances, on a case­by­case basis. They 
indicate that under certain circumstances they may decide 
to provide PTA. Sanofi shared a part of an Internal Quality 
Document on Informed Consent recently validated by 
the internal Bioethics Committee. The document contains 
a certain number of principles, which are in the process 
of being integrated into operating procedures documents. 
The Internal Quality document’s section on Post­Trial 
Access clarifies Sanofi’s position in respect to the issue 
of post­trial access to investigational products, both in 
pre­approval studies and in post­marketing studies using 
locally licensed medicines. It reads: “Post­study access and 
participant follow­up arrangements can only be made on 
a disease­by­disease, compound­by­compound or study­
by­study basis”.60
The way GSK describes these circumstances in its policy 
summarises the various company positions very well: 
“There may be circumstances when there is a compelling 
medical rationale for patients who have derived a measur­
able medical benefit from an investigational compound 
during a clinical trial to continue to receive that compound 
(e.g. the illness being treated is life threatening or seriously 
debilitating and there are no other treatments available 
or there are significant risks in switching patients to alter ­ 
native treatments). When this is the case, GSK may extend 
a study to facilitate appropriate continued access to the 
investigational product. Alternatively, the availability of an 
expanded access programme may serve as a means of 
continued access”.61
If we summarise the information that is available in policies 
and that was obtained through interviews with companies, 
we see a standard practice emerging. 
Companies consider providing PTA in case of non-licensed 
medicines until the medicines are approved and become 
licensed under the condition that:
	 The disease or condition being studied is serious or life 
threatening and/or long term.
	 The patient is benefiting and discontinuation of treat­
ment might adversely affect the patient’s health or 
well­being.
	 There is no (local) availability of alternative treatment.
	 There is sufficient efficacy and safety data and a positive 
benefit­risk balance.62
Companies consider providing PTA in case of licensed 
medicines (i.e. with marketing authorisation in the country) 
when the four conditions occur and patients still do not 
have access to the medicines despite the license, as in 
the situation where national health care does not fund it. 
However, this is considered even more exceptional. 
AstraZeneca: “If we decide to continue, then we 
make sure that it is up to the moment that the drug is 
authorized and we can bring the product in the market. 
And if we do a trial with a medicine that is already 
in the market, normally we will not provide further 
treatment. But even then, in certain exceptional 
 circumstances, we can decide to provide them to the 
patients who don’t have access to the medicine”.63
Merck: “In general, the provision of post-trial care for 
clinical trial participants continues under the applicable 
health care system of the host country.”64
GSK: “I think that most companies are very sympathetic 
to find a way to provide access when it’s a disease 
where patients are at acute risk of death or sickness. 
But I guess the problem is that most drugs are offering 
a benefit but there are still other treatments available 
that could be used. So I suspect that in most circum-
stances, patients fall back on (a) standard of care 
which may not have the new advantages of the new 
medicine but nonetheless provides some sort of 
reasonable cover.”65
The described nature of “exceptional circumstances” under 
which companies “may” (or may not) consider providing 
continued access to treatment after a clinical trial shows 
the freedom of the companies to make their own decisions 
about this because there are no binding regulations, except 
in Brazil. It also becomes clear that companies only consider 
PTA when the trial concerns a non­licensed drug. 
The provision of licensed drugs is seen as the responsibility 
of the government and national health­care systems. 
As Sanofi put it: “The company cannot replace the national 
health­care system”.66
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The preferred routes for PTA
The emerging standard practice for providing an unlicensed 
investigational drug until marketing approval is:
1 By enrolling the participants into a study extension 
(an Open Label Extension Study (OLE) or Long­Term 
Extension Study (LTE). 
2 Through one of the forms of Early Access Programmes 
(EAP), depending on the national regulatory framework 
in place. 
Related to point 2, in the US, the Food and Drug Admini­ 
stration (FDA) regulation67 allows access through “Expanded 
Access Programs”, while EU regulation68 allows such access 
through Compassionate Use Programmes (CUPs). There 
are Cohort CUPs (CUPs made available for groups of 
patients or hospitals on the basis of requests from physicians 
or companies69) and Named Patient CUPs (CUPs made 
available for individual patients on the basis of the 
 physician’s request70). 
AstraZeneca describe their practice as follows:  
“If a decision is made to continue to provide a clinical 
study drug after the original study is completed, we will 
ensure that appropriate oversight measures are in place, 
such as dispensing treatment in the context of a clinical 
study or a compassionate use programme.”72
Since Gilead mostly engage in the production of HIV and 
AIDS drugs, the company confirmed their coherence with 
the Good Participatory Practice issued by UNAIDS in 2011, 
where it is stated that post­trial access should be provided 
in the form of “follow on, open label, or other such studies 
before product licensure or approval”.73 It follows that 
Gilead’s way of allowing access to investigational drugs will 
be Gilead’s sponsored protocol. 
Novartis: “Where applicable, (…) research participants 
may, after trial completion, be offered participation in 
an extension study until marketing authorization.”74
Although considering Open Label Studies as their current 
standard, GSK seem to be in the process of considering 
a transition to a different practice. A spokesman said that, 
if an OLE is based only on the ethical need to supply the 
drug to the trial participants who benefited from the drug, 
then the drug should be provided with more clinical freedom 
and without the limitations of clinical trial protocols and 
the requirements for clinical data collection. Therefore the 
company’s standard may shift from an OLE to an Expanded 
Access Program. GSK has produced a new protocol on 
this topic, which is expected to be rolled out soon.75
PTA in LMICs
From what has already been discussed above, we can 
conclude that companies accept responsibility for PTA in 
principle but only under very specific and exceptional 
circumstances, on a case­by case basis and only until the 
investigational drug is licensed. The current shift of clinical 
trials to LMICs76 means that pharmaceutical companies 
increasingly have to deal with poor patients with limited 
access to health care (i.e. vulnerable groups) in their trials. 
Dealing with groups that are defined as vulnerable by the 
international ethical guidelines77 78 makes PTA even more 
relevant for these countries.
In their policies and in their interviews, all companies 
confirm that they apply the same ethical principles globally. 
When ethical standards cannot be upheld or where the 
local standard of care is unacceptably low, the common 
solution seems to be that companies avoid conducting 
trials in those places altogether. 
Gilead: “If local care would not be able to provide 
treatment follow up, then we would stop doing 
research in that site.”79 
Some of the companies in this research stated that, before 
doing research in an LMIC, they will obtain assurance that 
the local health­care system will be able to provide 
continued care. 
Characteristics of the most common PTA practices
Open Label Extension Studies (OLE) or Long-Term 
Extension studies (LTE)
Description: An extension of a clinical trial on the basis of a new 
study protocol in which the participant, health­care professional 
and others know the drug and dose being given (not blinded). 
Aim: It is conducted to assess the long­term safety and 
tolerability of an Investigational New Drug but is also used 
for continued prescribing of unlicensed medicines after a 
randomised trial to patients with medical need of the 
investigational medicine.
Compassionate Use Programs (CUP) or Expanded Access 
Programmes (EAP)
Description: An early access programme is a way of making 
a promising medicine available to patients when it has not yet 
been authorised (licensed) for their condition.71 
Aim: To make available unlicensed medicines on the basis of 
compassion but also used to provide a PTA. Compassionate 
Use Programmes and Expanded Access Programs can be 
considered substantially equivalent on the basis of the following 
characteristics: a) the compassion­based drug provision;  
b) the drug is not yet authorised; c) no alternative therapy 
is available; and d) there is no research objective or study 
protocol involved.
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GSK: “Responsibility for post-trial provision of nation-
ally licensed medicines used during a trial lies with 
governments as part of national healthcare programmes. 
For diseases/conditions that continue beyond the end 
of an interventional study, GSK-sponsored clinical trials 
will not be carried out unless we have assurance from 
the investigator that subjects will receive, or be referred 
for, any necessary continued healthcare and that the 
healthcare system is able to provide for the continued 
care of trial participants.”80 
Talking about unlicensed medicines, Sanofi says: 
“We ask ourselves whether we are dealing with a 
population that qualifies as vulnerable. Our position 
is to exclude vulnerable populations from these 
clinical trials”.81 
In relation to trials with licensed medicines in LMICs 
(but not limited to LMICs), Sanofi says that “participants 
will be included in a study only if they can indicate 
that they expect having, within the local healthcare 
system, access to continued care for their medical 
condition once they have completed their study  
(e.g. through public insurance, private insurance, out-of-
pocket payment, etc.)”. This is a recent decision which 
we are in the process of rolling out. The question will 
be directly asked to the patient by the investigator 
and this will be an inclusion criterion for the study. 
We discussed at length whether we would require actual 
documentation that post-trial access will be guaranteed 
(e.g. insurance contract, social security documents, etc...). 
This was seen as too complicated, given the variety of 
situations and countries in which we operate, and too 
much of a burden for patients.”82 
Roche write in their policy that their “preferred route 
is a written agreement obtained by the national health 
system assuring continuous medication and eligibility 
of all patients within national treatment systems, post 
completion of the Roche Sponsored Clinical Trial”.83
So we see that the way ‘guarantees’ are obtained by 
the companies differ (through the investigator, the patient 
or the national health system). However, they all ensure 
beforehand that it is the national health system that will 
be responsible for PTA in LMICs.
Examples of good PTA practice, 
as provided by the companies 
The intention of this research was to collect and publish 
the industry’s best practices in securing PTA, since there is 
to date no general consensus or overview about what best 
practices should look like. SOMO approached the largest 
companies in the sector and asked them to report their 
best practices, with only one condition: that the PTA should 
be arranged and financed by themselves and should be 
provided in LMICs (amongst others). This exercise proved 
very challenging as finding the knowledgeable people 
within the companies was difficult, and examples of good 
PTA practices were scarce.
Among the companies that participated in this research, 
only five were able or willing to provide cases of PTA. 
We collected a total of 13 cases. Gilead offered a large 
number of examples, but only one is an example of PTA 
exclusively financed by the company. Sanofi offered 
six cases (four Long­Term Extension studies and two 
Compassionate Use Programmes). One of each is presented 
in the table on page 11 and further. 
GSK provided SOMO with two cases. However, one falls 
outside our scope. The one excluded is a case of Post­
Approval Commitment study, requested by the EMA prior 
to final authorisation of the drug, and therefore cannot be 
counted as PTA. Novartis mentioned a number of roll­over 
protocols84 and provided two examples, one of which is 
presented below. The excluded one is an Expanded Access 
Program for those who are not eligible to participate in 
clinical trials and also falls outside our scope. 
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High income countries Low and Middle Income countries
Is local standard of care acceptable?
Can assurances that local standard 
of care is able to provide continued 
treatmement be obtainted?
Company may consider PTA 
provisions
Are the following conditions all there?
1
The disease being studied is serious 
or life threatening
2
Discontinuing the treatment may cause 
adverse effects on patients’ health
3
There is no (local) availability 
of alternative treatment
4
There are sufficient efficacy and safety 
data and a positive benefit-risk balance 
5
Is the drug unlicenced?
NO
NO TRIAL
TRIAL
NO PTA LTE CUP
NO
NO
YES
YES
YES
PTA decision tree based on SOMO’s analyses of company policies
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ClinicalTrials.gov identifier: NCT0015882185
 Company: Gilead Sciences
 Drug brand name: Viread®
 Generic name: tenovofir disoproxil fumarate (TDF)
 Disease: HIV
 Countries: US, Brazil, Argentina, Dominican Republic 
 Enrolled: 180 
 Date: Start date March 2000, primary completion date December 2011
Long-Term Extension Studies
Related to the provision of PTA, Gilead indicate that: 
“One of the issues is that you can only administer an 
investigational drug under protocol. So if you do a study 
and you finish the study, for those patients to access the 
drug, you can’t just provide it. It has to be administered 
under a protocol. Authorities usually do not give special 
authorization; it’s a highly regulated industry. It requires 
creating an open label protocol and collecting data 
and publishing the results.”86
As an example of such situations, Gilead offered the 
case of Viread®. In 2000, Gilead started a randomised 
double blind clinical trial to demonstrate the greater 
efficacy and safety of Viread®, lamivudine and efavirenz, 
in comparison with a regimen of stavudine, lamivudine 
and efavirenz. The drug was tested on antiretroviral 
naïve HIV­1 infected patients in a study that was solely 
sponsored by Gilead. According to the company, PTA 
was provided to patients in the Dominican Republic 
and South America (Brazil and Argentina) for up to 
roughly 10 years post completion of the study financed 
by Gilead. “Since Viread® and Truvada®87 were not yet 
approved in these countries when the original 3 year 
blinded study was completed, these drugs were 
provided through an expanded protocol until the drug 
was marketed, as required by the laws of those countries.”
The study protocol submitted by Gilead to the clinical­
trials.gov database documents what the company 
stated in their interview and confirms that, after the 
original 144 weeks, the trial was extended as an open 
label study multiple times for a total of 480 weeks 
(about 10 years). In the first 246 weeks of extension, 
Gilead provided tenofovir DF in combination with 
lamivudine and efavirenz. In the last 144 weeks, only 
tenofovir DF was provided.
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ClinicalTrials.gov Identifier: NCT0154417988
 Company: AstraZeneca
 Drug: Iressa®89
 Generic name: gefitinib 
 Disease: (non small cell) lung cancer
 Countries: China, France, Germany, Hong Kong, Hungary, Italy, Japan, Korea, Russia, Spain, Taiwan
 Enrolled: 287
 Date: Started March 2012, estimated study completion date January 2016
ClinicalTrials.gov identifier: NCT0071293390
 Company: GlaxoSmithKline
 Drug brand name: Benlysta®
 Generic name: belimumab
 Disease: systemic lupus erythematosus 
 Countries: United Kingdom, Slovakia, Germany, US, Austria, Korea, Colombia, Chile, Spain, Netherlands, 
Taiwan, Italy, Poland, Philippines, Argentina, Hong Kong, India, Brazil, Canada, Romania, Mexico, Israel, Russia, 
Sweden, Belgium, Peru, Czech Republic
 Enrolled: 733
 Date: Start date June 2008, estimated primary completion date March 2015
Long-Term Extension Studies
Iressa® is a drug that is used to treat adults with non 
small cell lung cancer and was granted marketing 
authorisation by the EMA on 24 June 2009. 
AstraZeneca provided a quote from an Iressa® study 
that is being conducted in China (and other sites) to 
illustrate how PTA is included in clinical trial protocols, 
although the protocol published in the clinicaltrial.gov 
database does not enclose the relevant quote. In their 
interview with SOMO, AstraZeneca stated that in every 
clinical trial and in every country where a trial is carried 
out, there will be a similar quote to the following:  
“After the study analysis for PES and OS, patients will 
have their treatment unblinded. Patients receiving 
gefinitib and still considered to be gaining benefit will 
be provided an option for continued gefitinib treatment. 
This will be via the standard commercial and reimburse­
ment routes or via open label study supply if the commer­
cial supply route is not possible.” (Revised Clinical Study 
protocol, Drug substance: Iressa, Study Code 
D791LC00001, Edition Number 3, Date: 8 April 2013).
GlaxoSmithKline stated that the company is running 
a “large post approval commitment program with 
Benlysta”.91 They also stated that post­approval extension 
studies on Benlysta® are also being conducted, indepen­
dently of an approval commitment. As an example, the 
company indicated how Benlysta® has been approved 
in Argentina since April 2012, but the extension study is 
still ongoing with the aim of ensuring participants have 
access to the drug. At the time of the interview, GSK 
said: “The current study was originally intended to run 
until approval from the local regulatory authorities. 
We are still trying to manage that and while that is 
going on, we haven’t stopped the extension study yet. 
We have kept it going significantly longer than planned 
because of patient access issues. We are currently 
looking to close the study and we are considering other 
options to ensure that the patients without reimburse-
ment to the drug are managed well. Until things become 
clear, we continue with the extension studies. In these 
studies, the drug is supplied through the continuation 
protocol with no charge to the patient.”92
Patients are now transitioning off the study and are 
in the process of seeking reimbursement through local 
standard of care.
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ClinicalTrials.gov Identifier: NCT0093055395
 Company: Sanofi 
 Drug: Lemtrada®
 Generic name: alemtuzumab 
 Disease: Relapsing­Remitting Multiple Sclerosis (RRMS) 
 Countries: Argentina, Austria, Australia, Belgium, Brazil, Canada, Croatia, Czech Republic, Denmark, France, 
Germany, Israel, Italy, Mexico, Netherlands, Poland, Russia, Serbia and Montenegro, Spain, Sweden, Ukraine, 
UK and US.
 Enrolled: 1,322
 Date: Start date August 2009, estimated completion date February 2016
ClinicalTrials.gov Identifier: NCT0174229993
 Company: Novartis
 Drug brand name: Glivec®
 Generic name: Imatinib
 Disease: cancer
 Countries: US, Switzerland, Turkey, United Kingdom, Thailand, China, Finland, France, Germany, Hong Kong, 
Romania, Singapore
 Enrolled: 149 (30 from China)
 Date: March 2013 – present
In this example, the PTA is provided through an open­
label extension study for multiple sclerosis patients 
who participated in one of three prior Sanofi sponsored 
studies of alemtuzumab (NCT00050778, NCT00530348 
and NCT00548405). As described in the protocol, 
the main purpose of this study is to examine long­term 
safety and efficacy of the drug. 
The alemtuzumab treatment offered will either be on a 
fixed schedule of two treatment cycles a year, or on an 
‘as needed’ schedule. There is no comparison treatment 
in this study. All patients will be required to return to 
their study site every three months for neurologic and 
other assessments. In addition, safety­related laboratory 
tests and surveys will be performed at least monthly. 
Participation in the extension study will last 48 months 
from enrollment. Study duration may be extended per 
protocol amendments to allow patients to remain in the 
study throughout the time of drug approval process or 
until a long­term follow up study is available in each 
respective country.96 
Novartis conducts roll­over protocols. These protocols 
allow patients to continue treatment and have access to 
drug after the parent (and extension trials) have finished. 
Novartis states that they have ongoing roll­over protocols 
with drugs such as Tasigna, Afinitor, Glivec, Panobinostat 
and Signifor, and others.  These roll­over protocols are 
compound­specific and are open to patients that have 
participated in a clinical trial with that compound, but 
that clinical trial has ended.  One example of such a 
programme is the Glivec (imatinib) roll­over protocol. 
Other countries that participate in this ongoing roll­over 
protocol, and that are not listed in the clinicaltrials.gov 
database, include Korea, India, Mexico, Peru and 
Argentina, as well as many other countries.94
Long-Term Extension Studies
 14Pharmaceutical sector SOMO Paper
ClinicalTrials.gov Identifier: NCT0125427997
 Company: Sanofi 
 Drug: Jevtana®98
 Generic name: cabazitaxel 
 Disease: Prostate cancer
 Countries: Argentina, Australia, Austria, Belgium, Bosnia, Bulgaria, Canada, Croatia, Czech Republic, Denmark, 
Finland, Hungary, India, Ireland, Italy, Kazakhstan, Luxembourg, Malaysia, Mexico, Netherlands, Philippines, 
Poland, Portugal, Romania, Serbia, Singapore, Slovakia, Sweden, Taiwan and UK
 Enrolled: 984
 Date: Started 17 December 2010, estimated completion date December 2014
Expanded Access Programme
Sanofi implemented an Expanded Access Programme 
study to provide early access to cabazitaxel in patients 
with metastatic hormone refractory prostate cancer 
previously treated with a docetaxel­containing regimen. 
As stated in the protocol submitted to the database 
clinicaltrial.gov, the primary outcome measure of this 
programme was to provide early access to cabazitaxel 
in patients with metastatic hormone refractory prostate 
cancer. The secondary outcome was to document the 
safety of cabazitaxel in those patients. 
In the study protocol, it is clearly stated that, in each 
country, patient recruitment ends when cabazitaxel 
becomes commercially available, but considering the 
timing or delay in getting approval and reimbursement 
in the participating countries, cabazitaxel was therefore 
administered through this early access programme. 
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Conclusions 
The current corporate practice
All the companies included in this research refer in their 
company policies to the Declaration of Helsinki (DoH), which 
includes the right to Post­Trial Access to Treatment (PTA). 
At the same time, the companies are very clear that PTA 
will only be provided in very specific circumstances on a 
case­by­case basis. The standard practice followed is that 
the provision of post­trial care for clinical trial participants 
continues under the applicable health­care system of the 
host country. Companies say in general that they only 
consider providing PTA themselves in case of non­licensed 
medicines for which no alternative treatments are available. 
This minimises the commitment to provide PTA enormously, 
since clinical trials testing new experimental drugs for 
which no alternative treatments exist are relatively scarce. 
In combination with the other mentioned conditions 
(the seriousness of the disease, the serious consequences 
of discontinuation and a positive benefit­risk balance), it is 
clear that provision for PTA arranged and paid for by a 
commercial sponsor is the exception rather than the rule. 
PTA is even more exceptional in low­ and middle­income 
countries (LMICs), where the need is much greater. Pharma­
ceutical companies do not want to become responsible for 
what they consider to be the responsibility of the national 
health­care system related to continuing treatment after 
clinical trials. This is the reason some companies give for 
avoiding conducting trials altogether in countries where 
the standard of care is too low to fulfill this responsibility. 
Other companies claim to exclude vulnerable people with 
limited access to health care from their trials altogether.
An extra step that companies take in LMICs is to obtain an 
assurance that the national health­care system will be able 
to provide continued treatment. This assurance may be 
obtained in different ways; from a written agreement with 
the national health system to a confirmation given by 
individual patients that they will have access to continuing 
treatment. (And therefore no PTA needs to be provided 
by the company in question.) 
The reliance on such assurances might be deceptive.  
In fact, populations in LMICs are considered to be particularly 
vulnerable on the basis of lack of access to quality health care 
due to economic factors (e.g. low personal income of the 
patients and/or no reimbursement possibilities). 
Reliance on a failing national health­care system can, in 
fact, result in the cessation of the care that was available 
during the trial. In LMICs, there is a greater appeal for the 
company to take responsibility for providing PTA. The focus 
of the companies on obtaining these assurances, however, 
seems to shy away from these responsibilities and instead 
push the problem off to the host countries and the patients 
themselves. 
Best practice?
The difficulty SOMO experienced in collecting good PTA 
examples from the companies in question and the absence 
of examples in the academic literature confirms the highly 
exceptional nature of PTA. The scarcity of PTA arrangements 
by commercial sponsors in LMICs is especially worrying. 
In those exceptional circumstances where a company has 
decided to arrange post­trial access to an unlicensed drug, 
it is done through an Open Label Extension Study or a 
Compassionate Use Programme. Open Label Extension 
Studies are the most common way to provide PTA in LMICs. 
However, ethical concerns voiced by academics, and to a 
certain extent also recognised by some companies, relate 
to the ambiguity between care and research in these studies. 
It is not always clear whether extension studies are done 
out of compassion or in order to gain long­term safety data 
for marketing reasons. The limited number of PTA arrange­
ments collected within this research has not provided 
enough information to identify elements of best practice. 
Recommendations for companies
Pharmaceutical companies should act with ‘due diligence’ 
in relation to the issue of PTA in line with the UN Guiding 
Principles on Business and Human Rights. ‘Due diligence’ 
is understood as a business process through which enter­
prises actively identify, prevent, mitigate and account for 
their potential and actual adverse human rights impacts. 
Proposed elements of best practice are presented in line 
with this concept. They are based on the review of the 
international ethical guidelines, the academic articles 
and company policies. 
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Elements for corporate best practice: 
Adequate policy commitment on PTA (publicly available).
 Minimal incorporating article 22 and 34 of the Declaration 
of Helsinki (DoH). 
 No limitation to provide PTA only in cases of non­licensed 
medicines for which no alternative treatment exists. 
This is too limited for LMICs as there is often also no 
affordable access to licensed medicines. 
 Including alternative treatments or other appropriate care 
and benefits when addressing the issue of PTA in LMICs.
Identification and assessment of potential and actual 
adverse human rights impacts.
 A realistic assessment of the post­trial situation of trial 
participants related to PTA, including questions such as: 
What does the local health­care system have to offer 
and do the participants have access to it? Will the drug 
being test be reasonably available for the benefit of the 
population or community where the research took place? 
 Assessments should include trials that are conducted 
by third parties on behalf of the company.
Prevention and mitigation.
 Advanced planning: before undertaking a clinical trial 
in a population or community with limited resources the 
commercial sponsor must plan whether, when and how 
provisions for PTA will be made available.
 In areas with limited resources, commercial sponsors 
should be willing in principle to take financial (co­)
responsibility for PTA arrangements and make these 
arrangements in cooperation with host country 
 governments and researchers prior to the trial.
 These arrangements should be described in the clinical 
trial protocols
 These arrangements should be described in the informed 
consent forms. Patients also need to be informed 
beforehand if PTA will not be provided. 
 The lack of PTA arrangements should be justified 
to research ethics committees.
Tracking performance and evaluation.
 Evaluation whether PTA has caused undue inducement.
 Evaluation whether PTA arrangements have delayed 
or prevented trials from happening.
 Evaluation if any negative impacts emanate from the 
situation that research (i.e. open­label extension studies) 
is used to provide care and treatment post­trial.
Transparency and communication about PTA arrangements.
 Offering access to information about PTA arrange­
ments. For instance to give stakeholders/civil society 
organisations (CSOs) access to clinical trial protocols 
and informed consent forms on request to check PTA 
arrangements. 
Effective grievance mechanism.
 The establishment of a grievance mechanism for 
participants who may be negatively impacted, so that 
grievances can be addressed early and remediated 
directly. 
Recommendations for other actors.
SOMO considers the following recommendations 
important for achieving better PTA practice in future:
 The International Conference on Harmonisation of 
Technical Requirements for Registration of Pharma­
ceuticals for Human Use (ICH) should consider including 
a section on PTA arrangements in their guidance 
documents, such as in the E3 guidelines for the clinical 
study reports and E6 guidelines for good clinical 
practice. As the ICH guidelines are incorporated into 
EU legislation, this would be binding in nature.
 The World Medical Association should consider 
re­adopting the language applied in the 2008 version 
of the Declaration of Helsinki and include again the 
wording “other appropriate care or benefits” as 
provisions of PTA.
 The World Health Organization (WHO) should consider 
including a field for PTA in the ‘WHO Data Set’ to 
increase transparency on PTA arrangements.
 (EU) Regulatory Authorities should ensure that the 
applicant for a marketing authorisation provides a 
description of the situation of trial participants with 
regard to PTA. Also, the applicant should describe the 
provisions made for post­trial access to treatment and 
medical care for study participants depending on their 
location and the treatment and medical care otherwise 
available. This information can form part of the clinical 
study report section on ethical considerations in 
accordance with ICH E3. 
 (EU) Regulatory Authorities should identify those studies 
that may give rise to special ethical concerns regarding 
access to post­trial treatment and, where applicable, 
to seek additional assurance that the solution was 
appropriate and ethically acceptable. 
 (EU) Regulatory Authorities should summarise this 
information in public assessment reports.99
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